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Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-a/5-fluorouracil
(5-FU) combination therapy for hepatocellular carcinoma (HCC). However, some IFNAR2-positive patients show no response to
the therapy. This result suggests the possibility of other factors, which would be responsible for resistance to IFN-a/5-FU therapy. The
aim of this study was to examine the mechanism of anti-proliferative effects of IFN-a/5-FU therapy and search for a biological marker
of chemoresistance to such therapy. Gene expression profiling and molecular network analysis were used in the analysis of non-
responders and responders with IFNAR2-positive HCC. The Wnt/b-catenin signalling pathway contributed to resistance to IFN-a/
5-FU therapy. Immunohistochemical analysis showed positive epithelial cell adhesion molecule (Ep-CAM) expression, the target
molecule of Wnt/b-catenin signalling, only in non-responders. In vitro studies showed that activation of Wnt/b-catenin signalling by
glycogen synthesis kinase-3 inhibitor (6-bromoindirubin-30-oxime (BIO)) induced chemoresistance to IFN-a/5-FU. BrdU-based cell
proliferation ELISA and cell cycle analysis showed that concurrent addition of BIO and IFN-a/5-FU significantly to hepatoma cell
cultures reduced the inhibitory effects of the latter two on DNA synthesis and accumulation of cells in the S-phase. The results
indicate that activation of Wnt/b-catenin signalling pathway induces chemoresistance to IFN-a/5-FU therapy and suggest that
Ep-CAM is a potentially useful marker for resistance to such therapy, especially in IFNAR2-positive cases.
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Interferon (IFN) is a regulatory cytokine with various cellular
activities, such as anti-proliferative, immunomodulatory and
anti-angiogenic activities (Baron and Dianzani, 1994; Gutterman,
1994). Several studies emphasised the strong anti-tumour activity
of IFN in hepatocellular carcinoma (HCC), when used in
combination with other chemotherapeutic agents (Patt et al,
1993; Obi et al, 2006). We also reported the clinical efficacy of IFN-
a/5-fluorouracil (5-FU) combination therapy for advanced
HCC (Miyamoto et al, 2000; Sakon et al, 2002; Ota et al, 2005;
Nagano et al, 2007a,b) and the mechanism of its anti-tumour
effects (Eguchi et al, 2000; Yamamoto et al, 2004; Kondo et al,
2005; Nakamura et al, 2007; Wada et al, 2007). Further studies
showed that the expression of IFN receptor type 2 (IFNAR2) in
HCC tissue samples correlates significantly with clinical response
to IFN-a/5-FU combination therapy (Ota et al, 2005; Nagano et al,
2007a). In an earlier study, we reported that 66% of those who
responded to such treatment were IFNAR2-positive, but half of
these 20 patients showed no clinical response (Nagano et al,
2007a). Therefore, finding novel biological markers of resistance to
IFN-a/5-FU combination therapy is desirable, not only so that
non-responders receive other potentially more successful treat-
ments, but also to avoid their suffering caused by debilitating side
effects.
Development of microarray technology has facilitated analysis
of genome-wide expression profiles (Zembutsu et al, 2002; Yang
et al, 2005). It can generate a large body of information concerning
genetic networks related to pathological subtype, prognosis and
resistance to anticancer drugs of neoplasm. We have reported
many studies using PCR array or oligonucleotide microarray
system in various human malignancies, particularly in gastro-
intestinal and HCCs (Komori et al, 2008; Kurokawa et al, 2004a,b;
Motoori et al, 2005, 2006). To understand the complex biological
processes, such as cancer progression and drug resistance, it is also
important to consider differential gene expression by the gene
network analysis (Kittaka et al, 2008). A detailed human
interactive network that captures the entire cellular network would
be invaluable in interpreting cancer signatures (Calvano et al,
2005; Rhodes and Chinnaiyan, 2005).
Received 5 January 2009; revised 9 March 2009; accepted 30 March
2009; published online 28 April 2009
*Correspondence: Dr H Nagano, Department of Surgery, Graduate
School of Medicine, Osaka University, 2-2, Yamadaoka E-2, Suita, Osaka
565-0871 Japan; E-mail: hnagano@gesurg.med.osaka-u.ac.jp
British Journal of Cancer (2009) 100, 1647–1658
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sIn this study, we applied the methods of oligonucleotide
microarray system and gene network analysis to identify
informative gene set(s) and signalling pathway(s) related to
resistance to IFN-a/5-FU combination therapy, especially in
patients with IFNAR2-positive HCC. The results showed that
Wnt/b-catenin signalling influenced resistance to IFN-a/5-FU
combination therapy. The study also investigated the potential
importance of epithelial cell adhesion molecule (Ep-CAM), which
is encoded by the TACSTD1 gene and confirmed as one of the
target genes of Wnt/b-catenin signalling (Yamashita et al, 2007), as
a biological marker for resistance to IFN-a/5-FU combination
therapy.
MATERIALS AND METHODS
Cell lines
The human HCC cell lines, PLC/PRF/5, HuH7, HLE, HLF and
HepG2, were purchased from the Japanese Cancer Research
Resources Bank (Tokyo, Japan). The Hep3B cell line was obtained
from the Institute of Development, Aging and Cancer, Tohoku
University (Sendai, Japan). They were maintained in Dulbecco’s
Modified Eagle Medium supplemented with 10% foetal bovine
serum, 100Uml
 1 penicillin and 100mgml
 1 streptomycin at 371C
in a humidified incubator with 5% CO2 in air.
Drugs and reagents
Purified human IFN-a was kindly supplied by Otsuka Pharmaceu-
tical Co. (Tokyo, Japan) and 5-FU was obtained from Kyowa
Hakko Co. (Tokyo, Japan). The small molecule of 6-bromoindi-
rubin-30-oxime (BIO), a specific inhibitor of glycogen synthesis
kinase-3 (GSK-3), activating the Wnt/b-catenin signalling pathway
(Sato et al, 2004), was purchased from Calbiochem (San Diego, CA,
USA) and was dissolved in dimethyl sulphoxide (DMSO) (Wako
Pure Chemical Industries, Osaka, Japan). We used the following
antibodies for immunohistochemistry and western blot analysis:
monoclonal mouse anti-human Ep-CAM antibody (Abcam,
Cambridge, UK), polyclonal rabbit anti-human c-MYC antibody
(Cell Signaling Technology, Beverly, MA, USA) and polyclonal
rabbit anti-human b-actin (Sigma, St Louis, MO, USA).
Patients and specimens
In total, 30 patients with multiple liver tumours spreading to both
lobes with tumour thrombi in the major branches of the portal
vein, underwent palliative reduction surgery at the Osaka
University Hospital as described in our earlier report (Nagano
et al, 2007a). All 30 patients had visible tumours in the remnant
liver, and received combination chemotherapy with 5-FU and
IFN-a as described earlier (Sakon et al, 2002; Ota et al, 2005). The
chemotherapeutic response was evaluated clinically according to
the criteria of the Eastern Cooperative Oncology Group (Oken
et al, 1982). In this study, responders were defined as patients with
complete response or partial response; non-responders were
defined as patients with stable disease or progressive disease. All
aspects of our study protocol were approved by the Human Ethics
Committee of Graduate School of Medicine, Osaka University,
Japan. Surgical specimens were obtained from these patients.
Appropriate informed consent was obtained from all patients.
For microarray analysis, we used samples of 18 cases that were
positive for IFNAR2 expression, whereas no samples were available
from 2 cases with insufficient quality of RNA. For reference in
microarray experiment, we obtained a mixture of RNA from
normal parts of the liver specimens of seven patients with liver
metastases from intestinal carcinomas who were free of HBV and
HCV infections. All tissues were snap-frozen into liquid nitrogen
and stored at  801C. Other samples were fixed in 10% buffered
formalin, embedded in paraffin and stained with haematoxylin–
eosin to study the pathological features of HCC in accordance with
the classification proposed by the Liver Cancer Study Group of
Japan.
Microarray experiments
The microarray experiments were conducted according to the
method described earlier (Kittaka et al, 2008). In brief, total RNA
was purified by TRIzol agent (Invitrogen, San Diego, CA, USA),
according to the instructions provided by the manufacturer. The
integrity of RNA was assessed by Agilent 2100 Bioanalyzer and
RNA 6000 LabChip kits (Yokokawa Analytical Systems, Tokyo,
Japan). Only high-quality RNA was used for analysis. For control
reference, RNAs from normal liver tissues were mixed. The
reference and sample were mixed and hybridised on a microarray
covering 30336 human probes (AceGene Human 30K; DNA Chip
Research Inc. and Hitachi Software Engineering Co., Kanagawa,
Japan). The ratio of expression level of each gene was converted to
a logarithmic scale (base 2) and the data matrix was normalised.
Genes with 410% missing data values in all samples were
excluded from analysis; a total of 14473 genes out of 30336 were
available for analysis.
To detect the significant genes for resistance, we used
permutation testing (Kurokawa et al, 2004b). The original score
of each gene (signal-to-noise ratio (S2N), Si¼(mA mB)/(sAþsB),
where m and s represent the mean and standard deviation of
expression for each class, was calculated without permuting labels
(responder or non-responder). The labels were randomly swapped
and the values of S2N were calculated between two groups.
Repetition of this permutation 10000 times provided data matrix
that was nearly the same as normal distribution. For each gene, the
P-value was calculated from the original S2N ratio with reference
to the distribution of permuted data matrix. We determined the
optimal P-value and the informative gene set.
Pathway analysis
We further analysed the significant genes for resistance by the
Ingenuity Pathways Analysis (Ingenuity Systems, Mountain View,
CA, USA; http://www.ingenuity.com). The Ingenuity Pathway
Knowledge Base (IPKB) is a database of earlier published findings
on mammalian biology. Canonical pathways analysis identifies the
pathways that were statistically significant from the submitted data
matrix from the canonical pathways of IPKB. The P-value of each
canonical pathway is calculated using Fischer’s exact test
determining the probability that the association between the genes
in the data set and the canonical pathway is because of chance
alone.
Network analysis was conducted as described earlier (Calvano
et al, 2005). In brief, the submitted genes that were mapped to the
corresponding gene objects in the IPKB were called ‘focus genes’.
The focus genes were used to generate biological networks. The
Ingenuity software queries the IPKB for interactions between focus
genes and then generates a set of networks. The P-value of each
network is calculated according to the fit of the user’s set of
significant genes. The score of a network is displayed as a negative
log of the P-value, indicating the probability that a collection of
genes equal to or greater than the number in a network could be
achieved by chance alone.
RT–PCR analysis
Complementary DNA was generated from 1mg RNA with avian
myeloblastosis virus reverse transcriptase (Promega, Madison, WI,
USA) as described earlier (Damdinsuren et al, 2006). Quantitative
real-time PCR (qRT–PCR) assays were carried out using the Light
Cycler (Roche Diagnostics, Mannheim, Germany), as described
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searlier (Ogawa et al, 2004). Gene expression was measured in
duplicate. The conditions set for qRT–PCR for TACSTD1, TCF3,
AXIN2, MYC, CCND1 and b-actin were one cycle of denaturing at
951C for 10min, followed by 40 cycles of 951C for 15s, 601C for 15s
and 721C for 35s, and final extension at 721C for 10min (or
annealing at 581C for b-actin). The primer sequences were as
follows: TACSTD1 forward primer, 50-TCCAGAAAGAAGAGA
ATGGCA-30; TACSTD1 reverse primer, 50-AAAGATGTCTTCGT
CCCACG-30; TCF3 forward primer, 50-ATCTGTGTCCCATGTCCC
AG-30; TCF3 reverse primer, 50-CCAGGGTAGGAGACTTGCAG-30;
AXIN2 forward primer, 50-GGTGTTTGAGGAGATCTGGG-30;
AXIN2 reverse primer, 50-TGCTCACAGCCAAGACAGTT-30; MYC
forward primer, 50-AAGAGGACTTGTTGCGGAAA-30; MYC reverse
primer, 50-CTCAGCCAAGGTTGTGAGGT-30; CCND1 forward
primer, 50-AAGGCCTGAACCTGAGGAG-30; CCND1 reverse primer,
50-CTTGACTCCAGCAGGGCTT-30; b-actin forward primer, 50-GA
AAATCTGGCACCACACCTT-30; and b-actin reverse primer, 50-G
TTGAAGGTAGTTTCGTGGAT-30.
Immunohistochemical staining
For immunohistochemical staining of Ep-CAM expression, we
used the method described earlier (Kondo et al, 1999) with minor
modifications. Briefly, formalin-fixed, paraffin-embedded 4-mm
thick sections were deparaffinised, then treated with an antigen
retrieval procedure and incubated in methanol containing 0.3%
hydrogen peroxide to block endogenous peroxidase. The sections
were incubated with normal protein block serum solution, and the
biotin-blocking solution (Wako) was used as recommended by the
manufacturer. Then, the sections were incubated overnight at 41C
with anti-Ep-CAM antibody as the primary antibody. After
washing in phosphate-buffered saline (PBS), the sections were
incubated with a biotin-conjugated secondary antibody (horse
anti-mouse antibody for Ep-CAM) and with peroxidase-conju-
gated streptavidin. The peroxidase reaction was then developed
with 0.02% 3, 30-diaminobenzidine tetrachloride (Wako) solution
with 0.03% hydrogen peroxide. Finally, the sections were counter-
stained with Meyer’s haematoxylin. For negative controls, sections
were treated the same way except that they were incubated with
Tris-buffered saline instead of the primary antibody.
Ep-CAM expression was assessed by two investigators (TN and
NM) independently without knowledge of the corresponding
clinicopathological data. Antigen expression was defined as the
presence of specific staining on the surface membrane of tumour
cells. Ep-CAM expression was evaluated by calculating the total
immunostaining score, representing the product of the proportion
score and the intensity score, as described earlier (Gastl et al,
2000). In brief, the proportion score described the estimated
fraction of positively stained tumour cells (0, none; 1, o10%; 2,
10–50%; 3, 50–80% and 4, X80%). The intensity of Ep-CAM
expression was compared with staining of normal bile duct
epithelium present in each section of positive control. The
intensity score represented the estimated staining intensity
(0, no staining; 1, weak; 2, moderate and 3, strong). The total
score ranged from 0 to 12. Ep-CAM-positive cases represented
those with a total score 44.
Western blot analysis
The cells were washed with PBS and collected with a rubber
scraper. After centrifugation, the cell pellets were resuspended in
RIPA buffer (25mM Tris (pH 7.5), 50mM NaCl, 0.5% sodium
deoxycholate, 2% Nonidet P-40, 0.2% sodium dodecyl sulphate,
1m M phenylmethylsulphonyl fluoride and 500 KIEml
 1 ‘Trasylol’
proteinase inhibitor (Bayer LeverKusen, Germany)) with phos-
phatase inhibitor (Sigma). The extracts were centrifuged and the
supernatant fraction was collected. Western blot analysis was
carried out as described earlier (Kondo et al, 2005).
Luciferase reporter assay
The reporter assay kit was purchased from SA Biosciences
(Frederick, MD, USA) to evaluate TCF/LEF transcriptional
activity and is used according to the instructions provided
by the manufacturer. In brief, 2 10
4 cells per well were added
in triplicate to a 96-well microplate, and 24h later, cells
were transiently transfected with the transcription factor-
responsive reporter or negative control by the Lipofectamine
2000 reagent (Invitrogen). Culture media were changed 16h after
transfection, and the transfected cells were treated with various
concentrations of BIO (0–5nM). After 24h treatment, luciferase
activity was measured with the Dual-Luciferase Assay System
(Promega) using microplate luminometer, microlumat LB96P
(Berthold Technologies, Calmbacher, Germany). The Firefly
luciferase activity, indicating TCF-dependent transcription, was
normalised to the Renilla luciferase activity as an internal control
to obtain the relative luciferase activity.
Growth-inhibitory assays with 5-FU and IFN-a
The growth inhibitory assay was assessed by the 3-(4-,
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
(Sigma) assay as described earlier (Eguchi et al, 2000). The tested
concentrations of 5-FU were 0.05, 0.5 and 5mgml
 1, and those of
IFN-a were 50, 500 and 5000Uml
 1. The cells were incubated in a
medium containing variable concentrations of 5-FU and IFN-a
with DMSO or 5nM BIO for 48h. The proportion of cells incubated
without drugs was defined as 100% viability.
DNA synthesis-inhibition assay
DNA synthesis inhibition was assessed by bromodeoxyuridine
(BrdU) incorporation rate using the Cell Proliferation enzyme-
linked immunosorbent assay (ELISA)-Chemiluminescent kit
(Roche Applied Science, Indianapolis, IN, USA) according to the
protocol provided by the manufacturer. In brief, HuH7 cells
(1 10
4 per well) were seeded in triplicate into 96-well microplate.
After treatment with control, 5-FU alone (5mgml
 1), IFN-a alone
(5000Uml
 1) and combination of 5-FU and IFN-a, with or without
BIO (5nM), the plates were incubated at 371C under 5% CO2 for
24h. Then cells were labelled for 2h with BrdU. Chemiluminescent
signals were detected on the microplate luminometer (microlumat
LB96P, Berthold Technologies).
Cell cycle analysis
Flow cytometric analysis was carried out as described earlier
(Eguchi et al, 2000). In brief, cells were washed with PBS and then
fixed in 70% cold ethanol. Propidium iodide (Sigma) and RNase
(Sigma) were added for 30min at 371C. Samples were filtered, and
data were acquired with a FACSort (Becton Dickinson Immuno-
cytometry Systems, San Jose, CA, USA). Analysis of the cell cycle
was carried out using ModFIT software (Becton Dickinson
Immunocytometry Systems).
Statistical analysis
Clinicopathological indicators were compared using w
2-test,
whereas continuous variables were compared using the Student’s
t-test. Survival curves were computed using the Kaplan–Meier
method, and differences between survival curves were compared
using the log-rank test. To evaluate the risk associated with the
prognostic variables, the Cox model with determination of the
hazard ratio was applied; a 95% confidence interval was adopted.
All statistical analyses were calculated using the SPSS software
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s(version 11.0.1 J, SPSS Inc., Chicago, IL, USA), and P-value o0.05
was considered statistically significant.
RESULTS
Patients’ characteristics
The characteristics of the 30 HCC patients are shown in Table 1.
A total of 10 patients were IFNAR2-negative and 20 patients were
IFNAR2-positive. In 20 cases with positive IFNAR2, 10 patients
were classified as responders; the remaining 10 patients were
classified as non-responders. All patients with negative IFNAR2
were non-responders. We have earlier reported that IFNAR2
expression correlated significantly with the response to IFN-a/
5-FU therapy (Ota et al, 2005; Nagano et al, 2007a). A larger
proportion of responders were infected with HCV than non-
responders. But all other analysed parameters were comparable
among these groups and there were no significant differences in
these parameters.
Microarray analysis and pathway analysis
Genes with significant P-values (Po0.001) were defined by the
random permutation test. These differentially expressed 161 genes
were selected as informative gene set and are listed in Table 2. The
status of gene expression was defined as expression in non-
responders compared with responders. Of the total, 98 genes were
relatively upregulated in the responder group and 63 genes were
relatively downregulated.
Then we carried out the canonical pathway analysis of the 161
genes using the software Ingenuity. Eight canonical pathways were
identified as pathways that significantly influenced the resistance
of IFN-a/5-FU combination therapy in 161 informative genes
(Table 3). We also simultaneously carried out network analysis of
the same informative genes set. A total of 14 networks were
identified, and these networks were ranked by the score on a
P-value calculation, which ranged from 2 to 55. Then, we selected
one network with the highest score. The network with the highest
score consisted of 35 molecules in 25 focus molecules and 11
interconnecting molecules (Figure 1A). This network included
AXIN2, TCF3, RARA, CREBBP and TACSTD1, which were all
associated with Wnt/b-catenin signalling identified by the
canonical pathway analysis. In recent reports, Wnt/b-catenin
signalling has been shown to mediate radiation resistance and
chemotherapy resistance of various malignancies. In the Wnt/b-
catenin signalling-related genes, TACSTD1 was most highly
upregulated in the non-responders at the level of transcription.
TACSTD1 expression by RT–PCR and correlation with
microarray data
Next, we examined the correlation between the expression data of
gene expression and qRT–PCR of TACSTD1 to verify the
microarray expression data. qRT–PCR analysis was carried out
on 13 HCC tissue samples with positive expression of IFNAR2.
Individual mRNA levels were normalised to b-actin and expressed
relative to those in a mixture of seven normal livers. In the 13
IFNAR2-positive samples, TACSTD1 expression correlated sig-
nificantly with the microarray data (Figure 1B). The Pearson
correlation coefficient (P-value) for TACSTD1 was 0.668
(P¼0.0107). We then analysed TACSTD1 expression according
to the clinical response to IFN-a/5-FU combination therapy.
TACSTD1 expression was higher in several non-responders with
IFNAR2-positive HCC or IFNAR2-negative HCC, compared with
responders with IFNAR2-positive HCC (Figure 1C). Using a
cut-off value of 10 for TACSTD1 expression ratio, it was possible
to exclude some non-responders from patients with IFNAR2-
positive HCC.
Immunohistochemical staining for Ep-CAM
We examined the Ep-CAM expression in 30 HCC patients who
underwent palliative reduction surgery. In tumour lesions, Ep-
CAM staining was specifically observed on the plasma membrane
of cancer cells. In Figure 1D (left), strong Ep-CAM expression was
noted in 80% of cancerous tissue in the representative case of non-
responders with IFNAR2-negative HCC. On the other hand, no Ep-
CAM expression was evident in the representative case of IFNAR2-
positive responders (Figure 1D, right). Among the 30 patients
examined, Ep-CAM expression was observed in six (20%). It is
important that Ep-CAM expression was associated with resistance
to IFN-a/5-FU therapy, and no Ep-CAM expression was noted in
the responders (Table 4). However, the difference in the expression
Table 1 Clinicopathological characteristics of responders and non-
responders
IFNAR2-positive IFNAR2-negative
Responders
(n¼10)
Non-
responders
(n¼10)
Non-
responders
(n¼10) P-value
Age (year) NS
o60 6 7 5
X60 4 3 5
Sex NS
Male 9 9 9
Female 1 1 1
HBV infection NS
Present 6 8 7
Absent 4 2 3
HCV infection 0.0180
Present 7 1 3
Absent 3 9 7
Child-pugh score NS
A7 7 5
B, C 3 3 5
Liver cirrhosis NS
Present 4 7 3
Absent 6 3 7
a-fetoprotein (ngml
 1)N S
o300 5 1 3
X300 5 9 7
Tumour size (cm) NS
o52 3 2
X58 7 8
Histological grade NS
Moderately
differentiated
10 0
Poorly
differentiated
98 9
Undifferentiated 0 2 1
IFNAR2 expression o0.0001
00 0 1 0
1 8 10 0
22 0 0
HBV¼hepatitis B virus; HCV¼hepatitis C virus; IFNAR2¼type I interferon
receptor 2.
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sTable 2 List of informative 161 genes defining responders and non-responders
Rank Status Gene symbol Gene name Ref Seq ID
1 Down — dj329l24.3 (member of mcm2/3/5 family) —
2 Down CREBBP CREB-binding protein (Rubinstein-Taybi syndrome) NM_004380
3 Down C20orf116 Chromosome 20 open reading frame 116 NM_023935
4 Down — Ensembl genscan prediction —
5 Down SLC25A40 Solute carrier family 25, member 40 NM_018843
6 Up ZNF598 Zinc-finger protein 598 NM_178167
7 Down RCOR1 REST corepressor 1 NM_015156
8 Up TACSTD1 Tumour-associated calcium signal transducer 1 NM_002354
9 Down ZNF397 Zinc-finger protein 397 NM_032347
10 Down RTP3 Receptor (chemosensory) transporter protein 3 NM_031440
11 Up AARS2 Alanyl-tRNA synthetase 2, mitochondrial (putative) NM_020745
12 Down RARA Retinoic acid receptor, alpha NM_000964
13 Up — DNA segment on chromosome 4 (unique) 234 expressed sequence NM_014392
14 Up CASP7 Caspase 7, apoptosis-related cysteine peptidase NM_033339
15 Up AZIN1 Antizyme inhibitor 1 NM_148174
16 Down — Ensembl prediction —
17 Down — Ensembl genscan prediction —
18 Up PABPN1 Poly(A)-binding protein, nuclear 1 —
19 Down NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q reductase) NM_024407
20 Down C9orf142 Chromosome 9 open reading frame 142 NM_183241
21 Down — Ensembl genscan prediction —
22 Up SNX21 Sorting nexin family member 21 NM_001042632
23 Down C12orf47 Chromosome 12 open reading frame 47 XR_017874
24 Down CCRL1 Chemokine (C–C motif) receptor-like 1 NM_178445
25 Down GLG1 Golgi apparatus protein 1 NM_012201
26 Down MRPS21 Mitochondrial ribosomal protein S21 NM_018997
27 Up ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2 NM_001606
28 Up AXIN2 Axin 2 (conductin, axil) NM_004655
29 Down — Ensembl genscan prediction —
30 Down NOXA1 NADPH oxidase activator 1 NM_006647
31 Down COX4I1 Cytochrome c oxidase subunit IV isoform 1 NM_001861
32 Up PCSK7 Proprotein convertase subtilisin/kexin type 7 XM_001128785
33 Up FABP3 Fatty acid-binding protein 3, muscle and heart (mammary-derived growth inhibitor) NM_004102
34 Down C20orf111 Chromosome 20 open reading frame 111 NM_016470
35 Down CAST Calpastatin NM_173061
36 Down C12orf47 Chromosome 12 open reading frame 47 XR_017874
37 Up — Hypothetical protein xp_032244 —
38 Down — Ensembl genscan prediction —
39 Up PCDHA1 Protocadherin alpha 1 NM_018900
40 Down MATK Megakaryocyte-associated tyrosine kinase NM_002378
41 Up — Hypothetical protein xp_051475 —
42 Up UBE2Q1 Ubiquitin-conjugating enzyme E2Q (putative) 1 NM_017582
43 Up GPATCH4 G patch domain containing 4 NM_182679
44 Down PARP2 Poly (ADP-ribose) polymerase family, member 2 NM_005484
45 Down HAL Histidine ammonia-lyase NM_002108
46 Up ASCC3 Activating signal cointegrator 1 complex subunit 3 NM_006828
47 Down KRTAP9-8 Keratin-associated protein 9–8 NM_031963
48 Up MAGED4B Melanoma antigen family D, 4B NM_030801
49 Down — Hypothetical LOC339123 NM_001005920
50 Down SPHK1 Sphingosine kinase 1 NM_021972
51 Up — Partial ighv ig h-chain v-region clone a81 —
52 Up CCDC109A Coiled-coil domain containing 109A NM_138357
53 Up GPR139 G protein-coupled receptor 139 NM_001002911
54 Up C1orf78 Chromosome 1 open reading frame 78 NM_018166
55 Down LRRC50 Leucine rich repeat containing 50 —
56 Down FAM125B Family with sequence similarity 125, member B NM_033446
57 Down IFT52 Intraflagellar transport 52 homolog (Chlamydomonas) NM_016004
58 Down C3orf36 Chromosome 3 open reading frame 36 NM_025041
59 Up GUCA1B Guanylate cyclase activator 1B (retina) NM_002098
60 Down EDF1 Endothelial differentiation-related factor 1 NM_003792
61 Down CCDC69 Coiled-coil domain containing 69 NM_015621
62 Down NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q reductase) NM_004553
63 Up CD93 CD93 molecule NM_012072
64 Down — Ensembl genscan prediction —
65 Down ENO2 Enolase 2 (gamma, neuronal) NM_001975
66 Down CDCP2 CUB domain-containing protein 2 —
67 Down — Ensembl genscan prediction —
68 Up — Similar to helicase-like protein nhl —
69 Down FOXN3 Forkhead box N3 NM_005197
70 Down DEF8 Differentially expressed in FDCP 8 homolog (mouse) NM_207514
71 Up — Hypothetical protein xp_034013 —
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Rank Status Gene symbol Gene name Ref Seq ID
72 Down TNS3 Tensin 3 NM_022748
73 Up FAM40A Family with sequence similarity 40, member A NM_033088
74 Down PRDM7 PR domain containing 7 NM_052996
75 Up — Hypothetical protein xp_039419 —
76 Up NNMT Nicotinamide N-methyltransferase NM_006169
77 Up RPL9 Ribosomal protein L9 —
78 Up ITM2C Integral membrane protein 2C NM_030926
79 Up — Ensembl genscan prediction —
80 Up BEX4 BEX family member 4 XM_936467
81 Up CSNK1G1 Casein kinase 1, gamma 1 NM_022048
82 Up EEF2K Eukaryotic elongation factor-2 kinase NM_013302
83 Down DNAJC8 DnaJ (Hsp40) homolog, subfamily C, member 8 —
84 Up GP5 Glycoprotein V (platelet) NM_004488
85 Down DPH3 DPH3, KTI11 homolog (S. cerevisiae) NM_001047434
86 Down — Ensembl genscan prediction —
87 Up RPS21 Ribosomal protein S21 —
88 Down — Kiaa1658 protein —
89 Down ADCYAP1R1 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I NM_001118
90 Down C5orf25 Chromosome 5 open reading frame 25 XR_015120
91 Down — PRO0132 protein NR_002763
92 Down FGF3 Fibroblast growth factor 3 (murine mammary tumour virus integration site (v-int-2) oncogene homolog) NM_005247
93 Up FABP7 Fatty acid-binding protein 7, brain NM_001446
94 Down HSD11B1 Hydroxysteroid (11–beta) dehydrogenase 1 NM_181755
95 Up — Chondroitin sulphate glucuronyltransferase NM_019015
96 Down OPTN Optineurin NM_001008213
97 Up — Erythroid differentiation-related factor 2 —
98 Down — Truncated alpha ig h-chain of disease patient har —
99 Down WT1 Wilms tumour 1 NM_024425
100 Down C8G Complement component 8, gamma polypeptide NM_000606
101 Down — pro1454 —
102 Down CADM1 Cell adhesion molecule 1 NM_001098517
103 Down GH1 Growth hormone 1 —
104 Down DNPEP Aspartyl aminopeptidase NM_012100
105 Up — Actin-like gene —
106 Down — Ensembl genscan prediction —
107 Down — Ensembl genscan prediction —
108 Up INTS4 Integrator complex subunit 4 NM_033547
109 Down SRA1 Steroid receptor RNA activator 1 NM_001035235
110 Down — Ensembl genscan prediction —
111 Up RPS25 Ribosomal protein S25 NM_001028
112 Down — KIAA1450 protein NM_020840
113 Up SH2D3C SH2 domain containing 3C NM_170600
114 Down NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 NM_018838
115 Down — NEFA-interacting nuclear protein NIP30 NM_024946
116 Down TDRD1 tudor domain containing 1 NM_198795
117 Down — 14a9ct dna sequence —
118 Up FBXW11 F-box and WD repeat domain containing 11 NM_012300
119 Down CBFA2T3 Core-binding factor, runt domain, alpha subunit 2; translocated to, 3 NM_005187
120 Down TCF3 Transcription factor 3 (E2A immunoglobulin enhancer-binding factors E12/E47) NM_003200
121 Down LASS5 LAG1 homolog, ceramide synthase 5 NM_147190
122 Down — Ensembl genscan prediction —
123 Up ACTR1B ARP1 actin-related protein 1 homolog B, centractin beta (yeast) NM_005735
124 Down — Hypothetical protein mgc5566 —
125 Up RPS4X Ribosomal protein S4, X-linked XR_019325
126 Down CDK6 Cyclin-dependent kinase 6 NM_001259
127 Up AVIL Advillin —
128 Down — Hypothetical protein xp_043732 —
129 Down C1orf136 Chromosome 1 open reading frame 136 —
130 Down — Hypothetical protein xp_043783 —
131 Down — Ews-fli-1 —
132 Up CDC42BPG CDC42-binding protein kinase gamma (DMPK-like) NM_017525
133 Down — Ensembl genscan prediction —
134 Down GDAP1L1 Ganglioside-induced differentiation-associated protein 1-like 1 NM_024034
135 Up C12orf4 Chromosome 12 open reading frame 4 NM_020374
136 Up KIAA0415 KIAA0415 NM_014855
137 Down PDLIM2 PDZ and LIM domain 2 (mystique) NM_198042
138 Down KHK Ketohexokinase (fructokinase) NM_006488
139 Down SLC36A1 Solute carrier family 36 (proton/amino acid symporter), member 1 NM_078483
140 Up — Hypothetical protein xp_050311 —
141 Up TBRG4 Transforming growth factor b regulator 4 NM_199122
142 Down — Rearranged vk3 of Hodgkin cell line —
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(P¼0.0528). In non-tumour lesions, Ep-CAM staining was
observed in a few scattered cells and proliferating bile duct
epithelium showed positive expression.
Analysis of the degree of Ep-CAM expression in tumour lesions
showed five (16.7%) samples negative for Ep-CAM expression
(score 0), 19 (63.3%) with weak expression (score 1–4), four
(13.3%) stained moderately (score 6–8) and two (6.7%) samples
exhibited strong Ep-CAM expression (score 9–12). These results
suggest that Ep-CAM expression in advanced HCC could be a
potentially useful marker for resistance to IFN-a/5-FU combina-
tion therapy.
Ep-CAM expression and activation of Wnt/b-catenin
signalling by BIO
We analysed the protein expression level of Ep-CAM in hepatoma
cell lines. Western blot analysis using an anti-Ep-CAM antibody
confirmed the positive expression of Ep-CAM in three of the six
cell lines (HuH7, HepG2 and Hep3B), whereas PLC/PRF/5, HLE
and HLF were negative (Figure 2A). We earlier reported strong
IFNAR2 expression in PLC/PRF/5 cells and weak IFNAR2
expression in HuH7 cells (Eguchi et al, 2000). We transfected a
TCF/LEF reporter into PLC/PRF/5, HuH7 and HepG2 cells to
evaluate TCF/LEF transcriptional activity, representing the activity
of Wnt/b-catenin signalling pathway. We found that the luciferase
activities were high in both Ep-CAM-positive HuH7 cells and
HepG2 cells, whereas very low in Ep-CAM-negative PLC/PRF/5
cells (Figure 2B). And, HepG2 cell line was reported to have
mutation and activated b-catenin (de La Coste et al, 1998). For
these reasons, we used the cell line HuH7 to investigate how Wnt/
b-catenin signalling affected on the growth-inhibitory effect of
IFN-a/5-FU. In the next step, we examined whether Wnt/b-catenin
signalling can be activated in HuH7 cells when treated with various
concentrations of specific GSK-3 inhibitor, BIO. HuH7 cells treated
with BIO showed a substantial, dose-dependent increase in TCF/
LEF reporter activity. Consequently, treatment with BIO at 0.5, 1
and 5nM induced 8.6-, 29.1-, and 48.6-fold increases in relative
luciferase activity compared with HuH7 cells treated by DMSO,
respectively (Figure 2C). To examine the effects of BIO on the
expression of Wnt/b-catenin signalling targeted genes, qRT–PCR
analysis of five targeted genes (TACSTD1, AXIN2, MYC, TCF3 and
CCND1) was carried out in HuH7 cells after 24h treatment with
BIO (5nM). The concentration of BIO was selected on the basis of
the results of luciferase reporter assay. Treatment with BIO
increased the mRNA expression of targeted genes from 1.3-fold to
7.6-fold compared with cells treated with DMSO (Figure 2D). In
western blot analysis, the expression levels of Ep-CAM and c-MYC
increased in a BIO dose-dependent manner in HuH7 cells, but not
in PLC/PRF/5 cells (Figure 2E).
Growth inhibition assay and reduction of
growth-inhibitory effect of 5-FU and/or
IFN-a treatment
Next, we investigated the role of activation of Wnt/b-catenin
signalling in the reduction of the growth-inhibitory effect of IFN-a/
5-FU. The growth of HCC cells (PLC/PRF/5 and HuH7 cell lines)
was suppressed by 5-FU and IFN-a in a dose-dependent manner.
Concurrent addition of BIO and IFN-a/5-FU to the cell cultures
significantly reduced the growth-inhibitory effects of IFN-a/5-FU
in HuH7 cells. In HuH7 cells, the growth inhibitory effects of IFN-
a/5-FU without BIO were 22.3±2.8% at 0.5mgml
 1 5-FU and 500
Uml
 1 IFN-a, and 44.6±0.9% at 5mgml
 1 and 5000Uml
 1.
Concurrent addition of BIO decreased the growth inhibitory effect
to 8.6±3.9% (P¼0.0012; 0.5mgml
 1 of 5-FU and 500 Uml
 1 for
IFN-a) and 29.0±2.0% (Po0.0001, 5mgml
 1 for 5-FU and 5000
Uml
 1 for IFN-a) of control cells. In contrast, no change in the
growth-inhibitory effect was found in PLC/PRF/5 cell line
(Figure 3A). We also investigated the effects of BIO when
combined with 5-FU alone or IFN-a alone in HuH7 cells. The
Table 2 (Continued)
Rank Status Gene symbol Gene name Ref Seq ID
143 Up CD59 CD59 molecule, complement regulatory protein NM_203330
144 Down PEX26 Peroxisome biogenesis factor 26 —
145 Up VEGFC Vascular endothelial growth factor C NM_005429
146 Down DTX2 Deltex homolog 2 (Drosophila) XM_941785
147 Up ELAVL3 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C) NM_032281
148 Up BSDC1 BSD domain containing 1 NM_018045
149 Down FUBP3 Far upstream element (FUSE)-binding protein 3 XM_001128545
150 Down CCDC48 Coiled-coil domain containing 48 NM_024768
151 Down EPHA6 EPH receptor A6 NM_001080448
152 Down ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 NM_003034
153 Down MKKS McKusick-Kaufman syndrome NM_018848
154 Down MGA MAX gene associated NM_001080541
155 Up — Hypothetical protein xp_040140 —
156 Down — Hypothetical protein xp_043452 —
157 Up MMP20 Matrix metallopeptidase 20 (enamelysin) NM_004771
158 Up SLC23A2 Solute carrier family 23 (nucleobase transporters), member 2 NM_005116
159 Up GABARAPL1 GABA(A) receptor-associated protein like 1 NM_031412
160 Down — Ensembl genscan prediction —
161 Up PKLR Pyruvate kinase, liver and RBC NM_000298
Ranking was according to absolute value of signal-to-noise ratio. Status was defined as expression in non-responders compared with responders.
Table 3 List of significant pathways from 161 informative genes by
canonical pathway analysis
Pathway P-value
Ubiquinone biosynthesis 0.0004
Oxidative phosphorylation 0.0074
Mitochondrial dysfunction 0.0095
FXR/RXR activation 0.0162
Wnt/b-catenin signalling 0.0170
Complement system 0.0191
Histidine metabolism 0.0263
Sphingolipid metabolism 0.0389
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reduced anti-proliferative effects (data not shown).
Activation of Wnt/b-catenin signalling interferes with
the inhibitory effect of IFN-a/5-FU on DNA synthesis
To investigate whether activation of Wnt/b-catenin signalling
is involved in the reduction of the growth inhibitory effects of
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Table 4 Immunohistochemical analysis of Ep-CAM expression
Ep-CAM expression
Negative Positive P-value
Responders 10 0 0.0528
Non-responders 14 6
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DNA synthesis using a BrdU-based cell proliferation ELISA. In
HuH7 cells, the BrdU incorporation rates (representing DNA
synthesis) in cultures treated with 5-FU alone and IFN-a/5-FU
were 0.649±0.052 and 0.312±0.004, respectively. Activation of
Wnt/b-catenin signalling by BIO resulted in a significant
interference with the inhibitory effect of IFN-a/5-FU on DNA
synthesis; the BrdU incorporation rates in cells cultured with BIO
and 5-FU alone and with BIO and IFN-a/5-FU were significantly
increased to 0.928±0.020 (P¼0.002) and 0.458±0.037 (P¼0.007)
(Figure 3B).
Cell cycle assay
Finally, we used flow cytometric analysis to examine changes in
cell cycle progression in cultures treated with BIO and IFN-a/5-FU.
In cultures refed with serum plus 5-FU and IFN-a, the distribution
of cells at different cell cycles was similar to that of cells treated
with DMSO at 12h. Thereafter, HuH7 cell lines treated with 5-FU
and IFN-a showed accumulation of cells in S-phase and a gradual
increase in S-phase fraction from 24 to 48h. Addition of BIO
and IFN-a/5-FU to the cell cultures delayed the accumulation of
S-phase fraction. Marked accumulation of cells in S-phase (24h;
69.4% and 48h; 92.9%) was noted in cultures of cells treated with
IFN-a/5-FU, whereas the percentage of cells in S-phase in cultures
of BIO and IFN-a/5-FU decreased to 34.9% and 62.9% at the
respective time points (Figure 3C).
DISCUSSION
Gene expression profiling analyses represent a high-throughput
approach to dissect the biology underlining resistance to antic-
ancer drugs in malignancies. We earlier identified a 63-gene set
that could predict the response to IFN-a/5-FU combination
therapy using a small-scale PCR array system of a total of 2666
genes (Kurokawa et al, 2004a). In this study, we used advanced
technology with human whole genes analysis covering 30,336
human probes compared with the PCR array system. This
comprehensive analysis allowed us to identify the biological
actions of IFN-a/5-FU combination therapy. Furthermore, creating
biological networks from comprehensive gene expression profiling
could be useful for discovering certain targeted molecules and
pathways. In fact, we reported recently genome-wide expression
profiling of 100 HCC tissues using this network analysis, Ingenuity
Pathway Analysis and identified novel targeted molecules related
to specific signalling pathways (Kittaka et al, 2008).
In this study, gene expression profiling and pathway analysis
identified Wnt/b-catenin signalling as a significant canonical
pathway. The Wnt/b-catenin-signalling pathway plays an impor-
tant role in the development of various malignancies, as well as cell
proliferation and differentiation in several adult stem cells (Barker
and Clevers, 2006; Klaus and Birchmeier, 2008). It has been also
shown that anti-cancer drugs or irradiation often kill tumour cells,
yet putative cancer stem/progenitor cells are resistant to these
agents (Jamieson et al, 2004; Woodward et al, 2007; Klaus and
Birchmeier, 2008). Cancer stem/progenitor cells provide an
attractive explanation for chemotherapy-induced tumour remis-
sion as well as relapse. Analysis of the molecular and signalling
mechanism of resistance of cancer stem/progenitor cells should be
important for the development of new therapeutic strategies.
Recent studies showed that the Wnt/b-catenin pathway plays a role
in radiation and/or chemotherapy resistance of various malig-
nancies such as leukaemia, head and neck tumours, prostate
cancer and HCC (Jamieson et al, 2004; Ohigashi et al, 2005; Chang
et al, 2008; Yang et al, 2008). In this study, we also showed that
activation of Wnt/b-catenin signalling by a specific GSK-3
inhibitor in hepatoma cell lines decreased the susceptibility to
IFN-a/5-FU through a reduction in their DNA synthesis inhibitory
effects and regulation of cell cycle progression. We have already
reported the mechanisms of the anti-proliferative effects of IFN-a/
5-FU combination therapy, including regulation of cell cycle
progression by increasing S-phase fraction (Eguchi et al, 2000),
induction of apoptosis through IFNAR2, by downregulating Bcl-xl
and by Fas/FasL pathway (Kondo et al, 2005; Damdinsuren et al,
2007; Nakamura et al, 2007; Nagano et al, 2007a), modulation of
the immune response by inducing the TRAIL/TRAIL-receptor
pathway (Yamamoto et al, 2004) and inhibition of tumour
angiogenesis (Wada et al, 2007). In addition to the above
mechanisms related to their anti-proliferative effects, this study
showed that activation of Wnt/b-catenin signalling resulted in
reduction of the inhibitory effects of IFN-a/5-FU on DNA
synthesis, by decreasing the accumulation of cells in S-phase.
With regard to the apoptotic effect of the combination therapy, it is
reported that Wnt/b-catenin signalling is closely linked to JAK–
STAT signalling (Yamashina et al, 2006), and regulates STAT3
expression, thus enhancing cell growth and anti-apoptotic activity
of various cancer cells (Kusaba et al, 2007). We earlier reported
that IFN-a/5-FU combination therapy increased the frequency of
apoptosis in PLC/PRF/5 cells, but only minimally in HuH7 cells
(o1%) (Eguchi et al, 2000). We also analysed the influence of
activation of Wnt/b-catenin signalling on the apoptotic effects of
IFN-a/5-FU combination therapy, but no significant change was
observed in HuH7 cells probably because of the low rate of
apoptosis. Further studies are needed to examine the molecular
mechanisms of Wnt/b-catenin signalling-related enhancement of
resistance to IFN-a/5-FU combination therapy.
Activation of the Wnt/b-catenin signalling pathway is reported
in various diseases including many malignancies (Moon et al,
2004; Reya and Clevers, 2005; Branda and Wands, 2006). The ideal
method for detecting the signalling activity in human tissues
remains controversial (Giles et al, 1980). A recent study identified
Ep-CAM as a novel Wnt/b-catenin signalling target gene in HCC
cell lines, which could also serve as a biomarker (Yamashita et al,
2007). Ep-CAM is a first tumour-associated antigen and encoded
by the TACSTD1 gene (Herlyn et al, 1979; Litvinov et al, 1994).
In liver neoplasia, Ep-CAM is expressed in almost all cholangio-
carcinomas, whereas 14% of HCCs manifested the expression,
which seems to be more pronounced in poorly differentiated
HCCs (Breuhahn et al, 2006). Ep-CAM-positive HCC displayed
a molecular signature with features of hepatic progenitor
cells, including the presence of known stem/progenitor markers
such as c-kit, cytokeratin 19. In earlier studies, we showed that
the expression of IFNAR2 is the only significant predictor
of clinical outcome of IFN-a/5-FU combination therapy
(Ota et al, 2005; Nagano et al, 2007a). On the basis of the present
results on 30 HCC tissue samples, Ep-CAM seems to be another
predictor of IFN-a/5-FU combination therapy. Further studies are
needed to validate this result using larger sample numbers to
establish the precise clinical response to IFN-a/5-FU combination
therapy.
In summary, we showed that activation of Wnt/b-catenin
signalling enhanced the resistance to IFN-a/5-FU therapy by
reducing the inhibitory effects of these drugs on DNA synthesis
and regulation of cell cycle progression in vitro. Furthermore, the
results identified Ep-CAM expression in HCC tissue specimen as a
potential biological marker for resistance to IFN-a/5-FU combina-
tion therapy.
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